Outcomes of Pediatric Patients With Hypertrophic Cardiomyopathy Listed for Transplant

Children with HCM listed for HTx age < 1 year and UNOS status 1 have the highest mortality awaiting HTx. A more rigorous identification of additional risk factors should be performed to better define timing of listing and which patient sub-group may derive optimal benefit from HTx.